

07 cells; and 3b shows that the monoclonal antibody produced by the A4.6.1 hybridoma inhibited the binding of hVEGF to the bovine ACE cells at a 1:250 molar ratio of hVEGF to antibody.--

At page 6, line 25, please delete "top panel" and replace therein with --12a--.

At page 6, line 26, please delete "bottom panel" and replace therein with --12b--.

In the Claims:

Please cancel claims 2, 22 and 24-26.

Please amend claims 1 and 8-10 as follows:

01 03 1. (amended) A method of treating a mammal having cerebral edema, comprising a) administering to said mammal an effective amount of hVEGF antagonist, wherein said antagonist comprises an [anti-VEGF] anti-hVEGF antibody; and b) determining the degree of cerebral edema; whereby the hVEGF antagonist reduces cerebral edema

02 04 8. (amended) The method of claim [7] 1 wherein said anti-hVEGF antibody comprises a chimeric murine antibody wherein at least one constant chain domain is replaced by the homologous human sequence.

9. (amended) The method of claim [7] 1 wherein said anti-hVEGF antibody comprises a humanized antibody.

10. (amended) The method of claim [7] 1 wherein said antibody comprises a monoclonal antibody.

II. REMARKS

Prior to the present amendments, claims 1, 2, 8-10, 22 and 24-26 were under consideration. By virtue of this Communication, claims 2, 22, 24-26 are cancelled. As such, claims 1, and 8-10 are subject to consideration.

The Brief Description of the Drawings in the specification has been amended to provide descriptions for individual panels within Figures 1, 3 and 12. Applicants submit that similar descriptions can be found elsewhere in the specification, for example, at page 31, lines 17 to page 32, line 2 (for Figure 1); page 34, lines 1-11 (for Figure 3); and page 41, lines 7-9 (for Figure 12).

Claims 1 and 8-10 have been amended to clarify the nature of the subject matter as claimed. Applicants note that support in the specification for the proposed amendments is found at least at page 13, lines 6-10; page 27, line 25 to page 28, line 2; and page 40, line 6 to page 41, line 23. With respect to canceled claims and all amendments, Applicants have not dedicated or